Impact of Agitator Design on Bioreactor Performance

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-05-15-2018
Volume 2018 eBook
Issue 1
Pages: 20–24

Aerobic bioprocesses are highly dependent upon the oxygen transfer rate (OTR) from sparged to dissolved gas. The relatively low solubility of oxygen, however, makes the choice of mixer impeller configuration a critical design factor for the bioreactor vessel. This article describes a series of experiments and computational fluid dynamics (CFD) simulations to detail the effect of mixer configuration on the efficiency and effectiveness of a bioreactor vessel with respect to blend time and mass transfer.

Aerobic bioprocesses are highly dependent upon the oxygen transfer rate (OTR) from sparged to dissolved gas. The relatively low solubility of oxygen, however, makes the choice of mixer impeller configuration a critical design factor for the bioreactor vessel. This article describes a series of experiments and computational fluid dynamics (CFD) simulations to detail the effect of mixer configuration on the efficiency and effectiveness of a bioreactor vessel with respect to blend time and mass transfer.

Read this article from Pharmaceutical Technology’s Biologics and Sterile Drug Manufacturing 2018 eBook.

Article Details

Pharmaceutical Technology
eBook: Biologics and Sterile Drug Manufacturing  
Vol. 42
May 2018
Pages: 20–24

Citation

When referring to this article, please cite it as A. Strand and N. Courtemanche, "Impact of Agitator Design on Bioreactor Performance," Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook (May 2018).

About the Authors

Aaron Strand, PE is a senior research engineer with SPX FLOW, aaron.strand@spxflow.com; Nicolle Courtemanche is a senior application engineer with SPX FLOW, nicolle.courtemanche@spxflow.com.

Recent Videos
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Related Content